MX2024008562A - Métodos para tratar o reducir el riesgo de rechazo del trasplante - Google Patents

Métodos para tratar o reducir el riesgo de rechazo del trasplante

Info

Publication number
MX2024008562A
MX2024008562A MX2024008562A MX2024008562A MX2024008562A MX 2024008562 A MX2024008562 A MX 2024008562A MX 2024008562 A MX2024008562 A MX 2024008562A MX 2024008562 A MX2024008562 A MX 2024008562A MX 2024008562 A MX2024008562 A MX 2024008562A
Authority
MX
Mexico
Prior art keywords
transplant rejection
risk
methods
treat
reduce
Prior art date
Application number
MX2024008562A
Other languages
English (en)
Spanish (es)
Inventor
John F Paolini
Muhammad M Mohiuddin
Original Assignee
Kiniksa Pharmaceuticals Gmbh
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiniksa Pharmaceuticals Gmbh, Univ Maryland filed Critical Kiniksa Pharmaceuticals Gmbh
Publication of MX2024008562A publication Critical patent/MX2024008562A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024008562A 2022-01-10 2024-07-08 Métodos para tratar o reducir el riesgo de rechazo del trasplante MX2024008562A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263298133P 2022-01-10 2022-01-10
US202263307911P 2022-02-08 2022-02-08
US202263327986P 2022-04-06 2022-04-06
PCT/US2023/060358 WO2023133577A1 (en) 2022-01-10 2023-01-10 Methods of treating or reducing risk of transplant rejection

Publications (1)

Publication Number Publication Date
MX2024008562A true MX2024008562A (es) 2024-12-06

Family

ID=87074361

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008562A MX2024008562A (es) 2022-01-10 2024-07-08 Métodos para tratar o reducir el riesgo de rechazo del trasplante

Country Status (8)

Country Link
US (1) US20230287132A1 (https=)
EP (1) EP4463182A1 (https=)
JP (1) JP2025502095A (https=)
KR (1) KR20240131437A (https=)
AU (1) AU2023205152A1 (https=)
CA (1) CA3242941A1 (https=)
MX (1) MX2024008562A (https=)
WO (1) WO2023133577A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2970493T (pt) * 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
WO2017040932A1 (en) * 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2023133577A1 (en) 2023-07-13
KR20240131437A (ko) 2024-08-30
AU2023205152A1 (en) 2024-07-18
JP2025502095A (ja) 2025-01-24
US20230287132A1 (en) 2023-09-14
CA3242941A1 (en) 2023-07-13
EP4463182A1 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
MX2024008562A (es) Métodos para tratar o reducir el riesgo de rechazo del trasplante
CL2023000095A1 (es) Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos
PE20081635A1 (es) Agentes para suprimir la reaccion de rechazo cronica
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
MX394043B (es) Inhibidores de mcl-1 indolicos sustituidos.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2020004140A (es) Composiciones y metodos para la eliminacion de celulas cd117+.
EA202192528A1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA202190094A1 (ru) Антитела против cd40 для применения в лечении аутоиммунного заболевания
BR112022024483A2 (pt) Métodos para tratar mieloma múltiplo
EA201890153A1 (ru) Ингибиторы поглощения глюкозы
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
EA202193111A1 (ru) Композиции и способы для лечения рака
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
MX2025013942A (es) Anticuerpos contra mucina 16 y metodos de uso de los mismos
CL2023003841A1 (es) Trampas de ligando del factor de crecimiento transformante beta para el tratamiento de enfermedades
MX378586B (es) Composición y método para el tratamiento de padecimientos de la piel
MX2025008017A (es) Uso de moduladores del receptor gabaa para el tratamiento del dolor
MX2023004113A (es) Metodo para el tratamiento de enfermedades relacionadas con ox40.
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX2023006704A (es) Composiciones dsg2 y metodos para el tratamiento de covid-19.
MX2022006812A (es) Metodos para tratar epoc mediante la administracion de un antagonista de il-33.